CLINICAL TRIALS PROFILE FOR BRIMONIDINE TARTRATE
✉ Email this page to a colleague
All Clinical Trials for BRIMONIDINE TARTRATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00061529 ↗ | A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension | Completed | Alcon Research | Phase 3 | 2003-01-01 | The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension. |
| NCT00121147 ↗ | Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan | Completed | Alcon Research | N/A | 2003-09-01 | The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan. |
| NCT00121147 ↗ | Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan | Completed | Hermann Eye Center | N/A | 2003-09-01 | The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan. |
| NCT00312416 ↗ | Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise | Completed | Medical University of Vienna | Phase 4 | 2004-02-01 | Brimonidine tartrate is an alpha-2 agonist ocular hypotensive drug that exerts its effect by causing both a decrease in aqueous production and an increase in uveoscleral outflow. It has been proven to reduce increased intraocular pressure in glaucoma and ocular hypertension. As an alpha 2 agonist Brimonidine belongs to the same class of drugs as Clonidine; however, its molecular structure is sufficiently different to make it more selective for the alpha 2 receptor than Clonidine. Unlike Clonidine, Brimonidine does not appear to have an effect on the central nervous system and therefore does not cause sedation or systemic hypotension. In addition to their known effect of lowering intraocular pressure, alpha 2 adrenoceptor agonists are neuroprotective. It has, however, been shown that Brimonidine is a very potent vasoconstrictor in the ciliary body thus reducing aqueous humor production. Little is, however, known about potential vasoconstrictor effects of Brimonidine in the posterior pole of the eye. This is of clinical importance, because optic nerve head ischemia appears to contribute to glaucoma pathophysiology. This study is performed to investigate the effects of topical Clonidine vs. topical Brimonidine on choroidal blood flow and intraocular pressure during isometric exercise. |
| NCT00413751 ↗ | Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes | Completed | Walter Reed Army Medical Center | 1969-12-31 | The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BRIMONIDINE TARTRATE
Condition Name
Clinical Trial Locations for BRIMONIDINE TARTRATE
Trials by Country
Clinical Trial Progress for BRIMONIDINE TARTRATE
Clinical Trial Phase
Clinical Trial Sponsors for BRIMONIDINE TARTRATE
Sponsor Name
